Akron Biotech of Boca Raton poised for growth

Posted by on Mar 28, 2015 in Newsroom | 0 comments

BOCA RATON, FL. – Claudia Zylberberg began her biotech firm in a one-room office in Boca Raton more than eight years ago. Today Akron Biotech, which produces cell cultures and other raw materials for government and pharmaceutical company research, is moving to a 10,000-square-foot laboratory and manufacturing space. Akron also is collaborating on research, including with a noted scientist from Florida Atlantic University in Jupiter. “I don’t want to be just a manufacturer of products, but an innovator as well,” Zylberberg said. Akron Biotech was recently noted by Palm...

Read More

Virginia Bio Announces THRiVE 2015 Bioscience Conference Featuring Governor Terry McAuliffe

Posted by on Mar 27, 2015 in Newsroom | 0 comments

RICHMOND, VA. – The Virginia Biotechnology Association (Virginia Bio), the premier statewide non-profit trade association representing the life sciences industry in the Commonwealth of Virginia, today announced that its bioscience centered THRiVE 2015 Conference will feature a Governor’s Forum on Bio and Big Data/Analytics with The Honorable Terry McAuliffe, Governor of the Commonwealth of Virginia. THRiVE 2015, to be held on April 23, 2015 at the Westfields Marriot Washington Dulles Conference Center in Chantilly, Virginia, will bring together bioscience leaders from across the...

Read More

FLAG Therapeutics Awarded a North Carolina Biotechnology Center Small Business Research Loan to Advance Its Lead Oncology Drug

Posted by on Mar 27, 2015 in Newsroom | 0 comments

RESEARCH TRIANGLE PARK, N.C. – FLAG Therapeutics Inc., a company focused on novel, bispecific oncology drugs, has received a $250,000 Small Business Research Loan (SRL) from the North Carolina Biotechnology Center. This capital will enable FLAG to pursue significant preclinical milestones to advance its lead bispecific anti-angiogenic/anti-tubulin (AA/AT) compound in preparation for an investigational new drug (IND) application and human clinical trials. A key US patent covering composition of matter for this compound FLAG-003 was issued last month and provides protection until June of...

Read More

Nanotherapeutics Closes Final Round of Financing for Completion of New Advanced Development and Manufacturing Facility

Posted by on Mar 18, 2015 in Newsroom | 0 comments

ALACHUA, FL. – Nanotherapeutics, Inc., an integrated biopharmaceutical company with a focus on advanced development and manufacturing, announced today that it has secured a $28.5 million debt financing from White Oak Global Advisors, LLC. The funds will support the completion of the Company’s 180,000 sq. ft. flexible biologics manufacturing facility located in Alachua. The NANO-ADM (Advanced Development and Manufacturing) facility, as it is known, will expand Nanotherapeutics’ core competencies in the development and cGMP manufacture of preclinical and clinical stage...

Read More

Xcelience to Expand HQ Ops and Hire 100

Posted by on Mar 16, 2015 in Newsroom | 0 comments

TAMPA, FL. – Pharmaceutical manufacturer Xcelience will add 100 jobs as it expands its Tampa headquarters, the company said Friday, as it capitalizes on a $9 million investment in its growth. The company said it will be hiring in drug development, manufacturing, quality assurance and packaging and will expand is manufacturing operations and pharmaceutical development labs. The new growth is a cornerstone of Florida Governor Rick Scott’s job creation plan and he said keeping Xcelience thriving and happy in the state will remain a priority. “We are proud to announce that...

Read More

AGTC Files Investigational New Drug Application for the Treatment of X-Linked Retinoschisis

Posted by on Mar 13, 2015 in Newsroom | 0 comments

GAINESVILLE, FL. – Applied Genetic Technologies Corporation (Nasdaq:AGTC), a clinical stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, today announced that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to conduct a Phase I/II clinical trial of the company’s gene therapy product candidate for the treatment of X-linked retinoschisis (XLRS). Utilizing technology licensed from the University ofFlorida, AGTC’s XLRS product candidate uses...

Read More